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Abstract: 
Hepatitis C viral infection is accompanied by various serum alterations that could explain its molecular impact 
on hepatic structure and metabolic homeostasis. Recently it has been shown that adipocytokines play a pivotal role in 
development  of  hepatic  steato-fibrosis,  different  studies  giving  a  support  of  the  hypothesis  that  the  balance  of 
adipocytokine expression is a key regulator for the progression of hepatic steatosis and fibrosis.  
The  association  between  insulin  resistance  and  hepatitis  C  virus  genotypes  and  liver  fibrosis  stage 
foreshadowed that virus-induced insulin resistance may be a mechanism for fibrogenesis in chronic hepatitis C virus 
infection. 
The main importance of adipocytokine profile detection consists in the prediction of steatosis induction that 
has clinical relevance, being associated with advanced fibrosis and hyporesponsiveness to antiviral therapy. 
 
Hepatitis C virus infection represents an issue with major impact on populational health in 
the entire world, due to its high infectious rate and the consequences of its offences brought to liver 
and extrahepatic tissue. 
The  plymorphic  manifestations  of  viral  hepatitis  C  plead  for  the  hypothesis  of  some 
extremely complex pathogenic mechanisms, which are variably influenced by standard antiviral 
treatment.  The  evolution  of  present  diagnosis  concepts  is  directed  towards  avoiding  potentially 
invasive maneuvers and also towards possibly putting to good use potential markers which certify 
the nature of infection and become predictive factors of response to treatment. 
High therapeutic costs, as well as the adverse effects that can be quite notable compel to the 
assay  and  development  of  some  hypotheses  that  correlate  genetic,  biochemical,  immune  and 
imaging    traits  of  the  viral  infection  with  the  potential  seriousness  of  manifestations  and  the 
response to treatment. Although the efficacy of interferon therapy in chronic hepatitis C is proven in 
numerous clinical trials, there are still many cases of dissatisfactory responses to this therapy [1]. 
Biochemical alterations that accompany the viral replication are insufficiently known up to 
this day. Infection with hepatitis C virus encloses a lot of metabolic effects which are correlated 
with the accumulation of fat in vitro and in vivo, changes in lipidic serum profile along with the 
presence of a certain degree of fatty liver uptake [2, 3]. 
Many studies have tried to bring to light the pleiotropic effects of C virus replication in 
order to establish connections between viral load levels and the presence of various manifestations. 
  It is presently well known the existing association among the different virus genotypes and 
the  level  of  fat  upload  in  the  liver  as  well  as  the  various  levels  of  response  to  the  antiviral 
conventional treatment [3, 4, 5]. 
Different links with lipidic profile alterations have raised a particular interest as they have 
offered, at least partially, explanations concerning the mechanism of viral operation [6, 7]. 
  The effects of hepatitis C virus on fat metabolism are partially identified. It is consentingly 
accepted the fact that the C virus induces the accumulation of lipids and that there is clearly a 
connection between the viral genotype and the level of lipidic upload in the liver. Genotypes Ib, IIIa 
and IIIh are connected with the increase of triglycerides, which can give explanations concerning 
the induction of liver steatosis associated with hepatitis C, as genotype III is connected with a 
„viral” type of steatosis and the other HCV genotypes with a „metabolical” type of steatosis [7, 8]. 
  Other observations on metabolic effects have distinguished the fact that HCV presence goes 
along with low serum cholesterol and apolipoprotein B levels, and that the response to the antiviral Journal of Medicine and Life  Vol. 1, No.1, January-March 2008 
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treatment seems to have a reversible result on these alterations of lipidic metabolism [8, 9]. 
  Various explanations have been sought to connect the presence of the virus to the lipidic 
profile,  like  the  existence  of  oxidative  stress  caused  by  the  increase  of  lipid  peroxidation,  a 
mechanism which can be involved in the pathogenesis of hepatitis C [9,10]. 
  There has even been an elaboration of a hypothesis concerning the connection between the 
rise  of  serum  cholesterol,  during  and  after  interferon  therapy,  with  the  activity  of  serum 
colinesterase. 
  The significant alterations that viral replication induces on liver cell architecture, evaluated 
in  standard  histological  scores  of  necrotic  and  inflammatory  activity,  steatosis  and  degree  of 
fibrosis, denotes the presence of extremely complex cellular and metabolic signal mechanisms. 
In  the  circumstances  of  dismetabolic  factors  absence,  well  known  as  inductors  of  fatty 
deposits in the liver as well as in the presence of low or normal levels of serum cholesterol (which 
are frequently correlated with an intense viral replication), the mechanism of  steatosis induction in 
the  liver  seems  to  be  completely  different  than  the  one  in  diabetes  mellitus  or  the  one  in  the 
metabolic disfunctions of other causes [11, 12, 13, 14, 15]. 
In this aspect, the investigation of serologic markers to be associated with the tendency of 
lipid  accumulation  in  the  liver,  in  comparison  with  the  cytokines  involved  in  the  steatosis  of 
diabetes mellitus, looks extremly stimulating. 
The prevalence of hepatic steatosis is established to be increased by obesity and DM, with 
plain fatty liver or nonspecific inflammatory steatosis having a better long term prognosis, while 
non-alcoholic steato-hepatitis (NASH) may lead to cirrhosis. 
Risk factors for NASH are represented by DM, BMI over 25 kg/m2 and central obesity [16, 
17, 18]. Insulin resistance appears to be the main factor involved in the complex pathogenesis of 
fatty liver, and its association with the presence of HCV determines a low rate of response to the 
standard  antiviral  therapy,  although  insulin  resistance  that  accompanies  HCV  infection  is 
incriminated as a risk factor for the development of DM in the carriers of infection [19]. 
Insulin resistance expressed in hepatocytes constitutes the result of alterations in a group of 
serologic and local factors such as hyperglicemia, hyperinsulinemia, the formation of advanced 
glycation  compounds,  the  rise  of  free  fatty  acids  and  their  metabolic  outputs,  the  increase  of 
oxidative stress as well as the altered adiponectin profile. 
The stellate cells are not only passive witnesses of these processes but also target cells that 
have  the  ability  to  respond  to  pathogenic  alterations  that  appear  simultaneously  with  the 
development of insulin resistance 
There are more than one mechanisms that act individually and in combination to determine 
an inhibiton of the insulin signaling sequence. Fatty tissue represents a key site for the interaction of 
adipokines with inflammation and immune cells, having a role in the production of adipocytokines. 
These peptides have an extremely important function in modeling the sensibility to insulin, the 
lipidic metabolism as well as the immune and inflammatory reactions. Changes in their secretion is 
most relevant in obesity and in metabolic syndrome [20, 21]. 
Adiponectin is the most abundant adipokine in plasma and its production decreases in the 
context of obesity and insulin resistance. It has anti-inflammatory qualities and an effect in the rise 
of hepatocyte sensitivity to the gluconeogenesis inhibition mediated by insulin. Due to its complex 
mechanisms of action in hepatocytes, mediated by the adipo R2 receptor, adiponectin fights the 
lipid  uptake  within  these  cells.  It  is  reckoned  that  liver  tissue  that  is  uploaded  with  fat  in  the 
presence of peripheral insulin resistance, is comparable with fat tissue. Liver inflammation and 
fibrosis  can  be  a  consequence  of  its  exposure  to  metabolic  and  pro-inflammatory  mediators 
produced by visceral fat and brought at this level through the portal venous system [20, 21, 22]. 
While  cytokines  like  TNF-alfa  and  IL1  have  a  profibrotic  effect  and  determine  insulin 
resistance,  adipocyte  hormones  have  an  opposite  result;  leptin  and  visfatin  improve  insulin 
resistance, while adiponectin and resistin increase it and have an anti-fibrosis effect. There are also 
many  other  molecules  which  have  only  partially  known  effects,  like  adipsin,  PAI-1  and 
angiotensinogen. Journal of Medicine and Life  Vol. 1, No.1, January-March 2008 
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Multiple  experiments  carried  out  on  animals  have  shown  that  leptin  is  a  mediator  of 
fibrogenesis  and  repair  through  fibrosis  of  tissular  injuries.  There  isn’t  yet  a  strict  correlation 
between serum concentration of leptin and the level of activation of its hepatocyte receptor, where 
there can be induced a local production or/and an increased  accumulation of  leptin. Although 
steatosis and fibrosis have insufficiently elucidated mechanisms, they seem to be pathogenically 
independent of leptin, even though once the process has started, leptin determines an acceleration of 
fat uptake inside the hepatocytes, a process that is dependent also on the grade of the patient’s 
insulin resistance. In the future, it is considered that by selectively blocking leptin signaling in the 
stellate liver cells, an optimal therapy aimed against hepatic fibrosis may be developed. 
Also, free fatty acids and activation of inflammatory paths are other determining factors for 
the  progression  of  lesions  to  cirrhosis.  Other  molecular  structures  involved  directly  in  fibrotic 
regeneration are plasminogen activator inhibitor 1, chemotactic monocyte protein 1 as well as some 
cytokines with favourable effect on inflammation (TNF alfa, IL6) and fibrosis (TGF-beta) [25, 26]. 
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After Leclercq, 2007 
 
The increased expression of cytokine signaling, SOCS-1 and SOCS-3, is involved in the 
pathogenesis  of  metabolic  syndrome  and  insulin  resistance  by  means  of  their  ability  to 
simultaneously modulate insulin and cytokine signals alike [26, 27, 28]. 
Adipokines, SOSC-3 and hyperinsulinemia have been nominated as determining factors of 
the extent of fibrosis and of the unresponsiveness to pegylated interferon (PEG IFN), the result and 
duration of the antiviral treatment depending on the patient metabolic and nutritional status and on 
viral genotype. 
The increased expression of SOCS-3, induced by the obesity related to insulin resistance, 
through a rise in adipocyte secretion of TNF-alpha and leptin, appears to be one of the inhibiting 
factors  of  PEG  IFN  induced  signaling  path  through  the  lowering  of  nuclear  factor  STAT 
phosphorylation [29, 30, 31] 
The independent and inverse predictive role of adiponectin concerning the response to the 
antiviral therapy in hepatitis C is  to be  mentioned. Also, it is suggested that leptin may be an 
independently  predicitve  factor  of  unresponsiveness  to  PEG  IFN  although  the  pathogenic 
mechanism  is  incompletely  discovered.  The  induction  of  hepatic  expression  of  SOCS-3  may 
constitute an explanation. Recent studies have shown that patients with high levels of TNF-alpha 
had a poor response to viral therapy. 
As far as the ethiopathogenesis of steatosis in chronic viral hepatitis C goes, recent literature 
data indicate the involvment of the same mediators of metabolic syndrome, but also of the factors 
assosciated with oxidative stress, of the lipid peroxidation products as well as the role of hepatocyte 
apoptosis  and  of  stellate  cell  activation  with  the  increased  deposit  of  the  extracellular  matrix 
elements [32, 33]. 
In cohorts with genotype Ib HCV, which is predominant in our country, liver steatosis has 
been linked with metabolic factors that also had a negative impact on sustained response to antiviral 
treatment [34, 35]. 
HCV infection induces not only steatosis and increase in TNF-alfa serum levels but also the 
development of insulin resistance, the presence of steatosis being correlated with that of serum 
inflammation markers [36]. 
Taking  into  account  the  literature  data,  the  comparative  assesment  of  pro-fibrosis 
inflammation markers and of adipocyte cyotkines appears to have a great importance in establishing 
a parallel between the mechanism of steatosis induction in chronic hepatitis C and in DM. 
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